Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy

L. Querol, RA. Lewis, HP. Hartung, PA. Van Doorn, E. Wallstroem, X. Luo, M. Alonso-Alonso, N. Atassi, RAC. Hughes

. 2023 ; 28 (2) : 276-285. [pub] 20230531

Language English Country United States

Document type Case Reports, Clinical Trial, Phase II, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23011193

BACKGROUND AND AIMS: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-mediated disease of the peripheral nerves, with significant unmet treatment needs. Clinical trials in CIDP are challenging; thus, new trial designs are needed. We present design of an open-label phase 2 study (NCT04658472) evaluating efficacy and safety of SAR445088, a monoclonal antibody targeting complement C1s, in CIDP. METHODS: This phase 2, proof-of-concept, multicenter, open-label trial will evaluate the efficacy, and safety of SAR445088 in 90 patients with CIDP across three groups: (1) currently treated with standard-of-care (SOC) therapies, including immunoglobulin or corticosteroids (SOC-Treated); (2) refractory to SOC (SOC-Refractory); and (3) naïve to SOC (SOC-Naïve). Enrolled participants undergo a 24-week treatment period (part A), followed by an optional treatment extension for up to an additional 52 weeks (part B). In part A, the primary endpoint for the SOC-Treated group is the percentage of participants with a relapse after switching from SOC to SAR445088. The primary endpoint for the SOC-Refractory and SOC-Naïve groups is the percentage of participants with a response, compared to baseline. Secondary endpoints include safety, tolerability, immunogenicity, and efficacy of SAR445088 during 12-week overlapping period (SOC-Treated). Part B evaluates long-term safety and durability of efficacy. Data analysis will be performed using Bayesian statistics (predefined efficacy thresholds) and historical data-based placebo assumptions to support program decision-making. INTERPRETATION: This innovative trial design based on patient groups and Bayesian statistics provides an efficient paradigm to evaluate new treatment candidates across the CIDP spectrum and can help accelerate development of new therapies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011193
003      
CZ-PrNML
005      
20230801132849.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jns.12551 $2 doi
035    __
$a (PubMed)37119056
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Querol, Luis $u Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain $u Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain $1 https://orcid.org/0000000242898264
245    13
$a An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy / $c L. Querol, RA. Lewis, HP. Hartung, PA. Van Doorn, E. Wallstroem, X. Luo, M. Alonso-Alonso, N. Atassi, RAC. Hughes
520    9_
$a BACKGROUND AND AIMS: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-mediated disease of the peripheral nerves, with significant unmet treatment needs. Clinical trials in CIDP are challenging; thus, new trial designs are needed. We present design of an open-label phase 2 study (NCT04658472) evaluating efficacy and safety of SAR445088, a monoclonal antibody targeting complement C1s, in CIDP. METHODS: This phase 2, proof-of-concept, multicenter, open-label trial will evaluate the efficacy, and safety of SAR445088 in 90 patients with CIDP across three groups: (1) currently treated with standard-of-care (SOC) therapies, including immunoglobulin or corticosteroids (SOC-Treated); (2) refractory to SOC (SOC-Refractory); and (3) naïve to SOC (SOC-Naïve). Enrolled participants undergo a 24-week treatment period (part A), followed by an optional treatment extension for up to an additional 52 weeks (part B). In part A, the primary endpoint for the SOC-Treated group is the percentage of participants with a relapse after switching from SOC to SAR445088. The primary endpoint for the SOC-Refractory and SOC-Naïve groups is the percentage of participants with a response, compared to baseline. Secondary endpoints include safety, tolerability, immunogenicity, and efficacy of SAR445088 during 12-week overlapping period (SOC-Treated). Part B evaluates long-term safety and durability of efficacy. Data analysis will be performed using Bayesian statistics (predefined efficacy thresholds) and historical data-based placebo assumptions to support program decision-making. INTERPRETATION: This innovative trial design based on patient groups and Bayesian statistics provides an efficient paradigm to evaluate new treatment candidates across the CIDP spectrum and can help accelerate development of new therapies.
650    _2
$a lidé $7 D006801
650    _2
$a hormony kůry nadledvin $x terapeutické užití $7 D000305
650    _2
$a monoklonální protilátky $7 D000911
650    _2
$a Bayesova věta $7 D001499
650    _2
$a komplement C1s $7 D003173
650    12
$a chronická zánětlivá demyelinizační polyneuropatie $x farmakoterapie $7 D020277
650    _2
$a výsledek terapie $7 D016896
650    _2
$a ověření koncepční studie $7 D000075082
655    _2
$a kazuistiky $7 D002363
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lewis, Richard A $u Cedars Sinai Medical Center, Los Angeles, California, USA $1 https://orcid.org/0000000211404575
700    1_
$a Hartung, Hans-Peter $u Department of Neurology, Faculty of Medicine, Heinrich Heine University, Düsseldorf, Germany $u Brain and Mind Center, University of Sydney, Sydney, New South Wales, Australia $u Department of Neurology, Medical University of Vienna, Vienna, Austria $u Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000206146989 $7 nlk20050167624
700    1_
$a Van Doorn, Pieter A $u Erasmus MC, University Medical Center, Rotterdam, The Netherlands $1 https://orcid.org/0000000325843357
700    1_
$a Wallstroem, Erik $u Neurology Development, Sanofi R&D, Cambridge, Massachusetts, USA
700    1_
$a Luo, Xiaodong $u Biostatistics and Programming, Sanofi R&D, Bridgewater, New Jersey, USA $1 https://orcid.org/0000000282149874
700    1_
$a Alonso-Alonso, Miguel $u Neurology Development, Sanofi R&D, Cambridge, Massachusetts, USA $1 https://orcid.org/0000000333729933
700    1_
$a Atassi, Nazem $u Neurology Development, Sanofi R&D, Cambridge, Massachusetts, USA
700    1_
$a Hughes, Richard A C $u UCL Queen Square Institute of Neurology, University College London, London, UK $1 https://orcid.org/0000000152513797
773    0_
$w MED00007709 $t Journal of the peripheral nervous system : JPNS $x 1529-8027 $g Roč. 28, č. 2 (2023), s. 276-285
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37119056 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132845 $b ABA008
999    __
$a ok $b bmc $g 1963528 $s 1197458
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 28 $c 2 $d 276-285 $e 20230531 $i 1529-8027 $m Journal of the peripheral nervous system $n J Peripher Nerv Syst $x MED00007709
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options